Skip to main
SRRK
SRRK logo

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding Corp demonstrates a positive outlook due to the encouraging Phase 3 SAPPHIRE data, which supports the likelihood of regulatory approval and potential commercial success, particularly in expanding its label for SMA treatment. The company's shares have increased by approximately 4%, reflecting market confidence, and analysts note that SRRK is trading at about 14x net cash, highlighting its perceived undervaluation and favorable risk/reward profile over the next 12-24 months. Furthermore, management has indicated successful resolutions to previous observations at their contract development and manufacturing organization (CDMO) facility, suggesting a strengthened operational foundation moving forward.

Bears say

Scholar Rock Holding Corp faces a negative outlook primarily due to the significant delay in the anticipated commercial launch of its lead product, apitegromab, which has been pushed back from the fourth quarter of 2025 to the second quarter of 2026 for the US and from the second quarter of 2026 to the third quarter of 2026 for the EU. This setback has resulted in a revised peak sales estimate of $1.7 billion by 2035, reflecting increased competitive risks and a potential new standard of care emerging in the near term. Additionally, the issuance of a Complete Response Letter (CRL) introduces further regulatory and pricing uncertainties, which raise concerns about SRK-181's market viability and the overall risk/benefit profile in ongoing and future indications.

SRRK has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 9 analysts, SRRK has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.